Evidence map›Paper›PMID 27757312›Full record

ArticleOncoimmunology

Activity and safety of radiotherapy with anti-PD-1 drug therapy in patients with metastatic melanoma.

E Liniker, A M Menzies, B Y Kong, A Cooper, S Ramanujam, S Lo, R F Kefford, G B Fogarty, A Guminski, T W Wang and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncoimmunology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 80 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
80citing papers in PubMed, 6 pooled it
10.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

80 citing papers in PubMed, 6 syntheses or guidelines pooled it, 150 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pulmonary complications of immune checkpoint inhibitors in patients with nonsmall cell lung cancer.European respiratory review : an official journal of the European Respiratory Society · 2019
    Pooled it
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article

20 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 1 country.

E LinikerMelanoma Institute Australia, The University of Sydney , Sydney, Australia.
A M MenziesMelanoma Institute Australia, The University of Sydney, Sydney, Australia; Royal North Shore Hospital, Sydney, Australia; Mater Hospital, Sydney, Australia.
B Y KongCrown Princess Mary Cancer Center , Westmead, Sydney, Australia.
A CooperCrown Princess Mary Cancer Center , Westmead, Sydney, Australia.
S RamanujamMelanoma Institute Australia, The University of Sydney , Sydney, Australia.
S LoMelanoma Institute Australia, The University of Sydney , Sydney, Australia.
R F KeffordMelanoma Institute Australia, The University of Sydney, Sydney, Australia; Crown Princess Mary Cancer Center, Westmead, Sydney, Australia; Macquarie University Health Sciences Centre, Sydney, Australia.
G B FogartyMelanoma Institute Australia, The University of Sydney, Sydney, Australia; Mater Hospital, Sydney, Australia.
A GuminskiMelanoma Institute Australia, The University of Sydney, Sydney, Australia; Royal North Shore Hospital, Sydney, Australia; Mater Hospital, Sydney, Australia.
T W WangCrown Princess Mary Cancer Center , Westmead, Sydney, Australia.
M S CarlinoMelanoma Institute Australia, The University of Sydney, Sydney, Australia; Crown Princess Mary Cancer Center, Westmead, Sydney, Australia.
A HongMelanoma Institute Australia, The University of Sydney, Sydney, Australia; Mater Hospital, Sydney, Australia.
G V LongMelanoma Institute Australia, The University of Sydney, Sydney, Australia; Royal North Shore Hospital, Sydney, Australia; Mater Hospital, Sydney, Australia.
Melanoma Institute Australia · AUCancer Australia · AUUniversity of Sydney · AURoyal North Shore Hospital · AUMacquarie University · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The anti-PD-1 antibodies nivolumab and pembrolizumab are active in metastatic melanoma; however, there is limited data on combining anti-PD-1 antibody and radiotherapy (RT). We sought to review clinical outcomes of patients receiving RT and anti-PD-1 therapy. All patients receiving anti-PD-1 antibody and RT for metastatic melanoma were identified. RT and systemic treatment, clinical outcome, and toxicity data were collected. Fifty-three patients were included; 35 patients received extracranial RT and/or intracranial stereotactic radiosurgery (SRS) and 21 received whole brain radiotherapy (WBRT) (three of whom also received SRS/extracranial RT). Patients treated with extracranial RT or SRS received treatment either sequentially (RT then anti-PD-1,

Indexed as

Anti-pd-1 antibodyimmunotherapymelanomaradiotherapy

Identifiers

PMID27757312
PMCPMC5048757
OpenAlexW2515622316

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.